Barbar T, Sathick IJ (2021) Tumor lysis syndrome. Adv Chronic Kidney Dis 28:438–446. https://doi.org/10.1053/j.ackd.2021.09.007

Article  PubMed  Google Scholar 

Gangani K, Fong HE, Faisaluddin M et al (2020) Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: a nationwide inpatient analysis. J Arrhyth 37:121–127. https://doi.org/10.1002/joa3.12482

Article  Google Scholar 

Howard SC, Avagyan A, Workeneh B, Pui CH (2024) Tumour lysis syndrome. Nat Rev Dis Primers 10:58. https://doi.org/10.1038/s41572-024-00542-w

Article  PubMed  Google Scholar 

Hande KR, Garrow GC (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med 94:133–139. https://doi.org/10.1016/0002-9343(93)90174-n

Article  CAS  PubMed  Google Scholar 

Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11. https://doi.org/10.1111/j.1365-2141.2004.05094.x

Article  PubMed  Google Scholar 

Kidney Disease Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138

Google Scholar 

Alhamid N, Sabbagh B, Alsarraj A et al (2024) Pitfalls of current diagnostic criteria of tumor lysis syndrome. Kidney Blood Press Res 49:266–272. https://doi.org/10.1159/000538328

Article  CAS  Google Scholar 

Lam AQ, Humphreys BD (2012) Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol 7:1692–1700. https://doi.org/10.2215/CJN.03140312

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778. https://doi.org/10.1200/JCO.2007.15.0177

Article  CAS  PubMed  Google Scholar 

El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A (2012) Acute kidney injury associated with tumor lysis syndrome: a paradigm shift. Am J Emerg Med 30:390.e3–6. https://doi.org/10.1016/j.ajem.2010.12.029

Article  PubMed  Google Scholar 

Shimada M, Johnson RJ, May WS Jr et al (2009) A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transpl 24:2960–2964. https://doi.org/10.1093/ndt/gfp330

Article  CAS  Google Scholar 

Khan RS (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8:75–88. https://doi.org/10.1007/s10157-004-0292-0

Article  CAS  PubMed  Google Scholar 

Durani U, Hogan WJ (2020) Emergencies in haematology: tumour lysis syndrome. Br J Haematol 188:494–500. https://doi.org/10.1111/bjh.16278

Article  PubMed  Google Scholar 

Lupusoru G, Ailincăi I, Frătilă G et al (2022) Tumor lysis syndrome: an endless challenge in onco-nephrology. Biomedicines 10:1012. https://doi.org/10.3390/biomedicines10051012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnaud M, Loiselle M, Vaganay C et al (2022) Tumor lysis syndrome and AKI: beyond crystal mechanisms. JASN 33:1154–1171. https://doi.org/10.1681/ASN.2021070997

Article  CAS  PubMed  PubMed Central  Google Scholar 

Findakly D, Luther RD, Wang J (2020) Tumor lysis syndrome in solid tumors: a comprehensive literature review, new insights, and novel strategies to improve outcomes. Cureus 12:e835. https://doi.org/10.7759/cureus.8355

Article  Google Scholar 

Lovelace K, vanGessel Y, Asher LV, Vogel P (2003) Spontaneous acute tumor lysis syndrome in a DBA/1J mouse: a case report and review. Toxicol Pathol 3:486–490. https://doi.org/10.1080/01926230390224674

Article  Google Scholar 

Kalemkerian GP, Darwish B, Varterasian ML (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103:363–367. https://doi.org/10.1016/s0002-9343(97)00153-8

Article  CAS  PubMed  Google Scholar 

Annemans L, Moeremans K, Lamotte M et al (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk Lymphoma 44:77–83. https://doi.org/10.1080/1042819021000054661

Article  CAS  PubMed  Google Scholar 

Drakos P, Bar-Ziv J, Catane R (1994) Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol 17:502–505. https://doi.org/10.1097/00000421-199412000-00010

Article  CAS  PubMed  Google Scholar 

Durani U, Shah ND, Go RS (2017) In-Hospital outcomes of tumor lysis syndrome: a population-based study using the national inpatient sample. Oncologist 22:1506–1509. https://doi.org/10.1634/theoncologist.2017-0147

Article  PubMed  PubMed Central  Google Scholar 

Calvache ET, Calvache ADT, Weber CS (2024) Tumor lysis syndrome in hematological inpatients, experience from a university hospital in Brazil: a retrospective cohort study. Hematol Transfus Cell Ther 46:340–344. https://doi.org/10.1016/j.htct.2023.02.005

Article  PubMed  Google Scholar 

Cairo MS, Thompson S, Stern L, Sherman S (2012) Incidence of treatment-related, laboratory and clinical tumor lysis syndrome. Blood 120:238. https://doi.org/10.1182/blood.V120.21.238.238

Article  Google Scholar 

Rios-Olais FA, Gil-López F, Mora-Cañas A, Demichelis-Gómez R (2024) Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia. Acta Haematol 147:391–401. https://doi.org/10.1159/000534453

Article  CAS  PubMed  Google Scholar 

Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95:563–573. https://doi.org/10.1007/s00277-015-2585-7

Article  CAS  PubMed  Google Scholar 

Xia S, Ma JT, Raschi E et al (2023) Tumor lysis syndrome with CD20 monoclonal antibodies for chronic lymphocytic leukemia: signals from the FDA adverse event reporting system. Clin Drug Investig 43:773–783. https://doi.org/10.1007/s40261-023-01308-0

Article  CAS  PubMed  Google Scholar 

Yang H, Rosove MH, Figlin RA (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 62:247–250. https://doi.org/10.1002/(SICI)1096-8652(199912)62:4%3c247::AID-AJH9%3e3.0.CO;2-T

Article  CAS  PubMed  Google Scholar 

Li D, Qin C, Wang H, et al (2024) Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA adverse event reporting system database. Ther Adv Drug Saf 15. https://doi.org/10.1177/20420986241274909

Sezer O, Vesole DH, Singhal S et al (2006) Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 7:233–235. https://doi.org/10.3816/CLM.2006.n.064

Article  CAS  PubMed  Google Scholar 

Kondo M, Hotta Y, Yamauchi K et al (2020) Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study. BMC Cancer 20:1117. https://doi.org/10.1186/s12885-020-07592-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bouclet F, Calleja A, Dilhuydy MS et al (2021) Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann Hematol 100:987–993. https://doi.org/10.1007/s00277-021-04419-w

Article  CAS  PubMed